Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00567047 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment
A Phase 1 study of Type 2 Diabetes, sponsored by Novartis.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 6
- Study locations
NCT00567047: Completed Phase 1 study of Type 2 Diabetes, sponsored by Novartis.
NCT00567047 is a Phase 1 study of Type 2 Diabetes that has completed, run by Novartis. The registered enrollment target is 96 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00567047, a Phase 1 study of Type 2 Diabetes, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study will evaluate the pharmacokinetics of vildagliptin and its metabolites in patients with mild, moderate or severe renal impairment and healthy volunteers.
Conditions Studied
Interventions
- DRUG vildagliptin
Study Locations (6)
Florida
- Novartis Investigator Site - Miami
- Novartis Investigator Site - Orlando
Minnesota
- Novartis Investigator Site - Minneapolis
Tennessee
- Novartis Investigator Site - Knoxville
Virginia
- Novartis Investigator Site - Richmond
Other
- Novartis Investigator Site - Kiel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2007-07 |
| Phase | Phase 1 |
What the finished NCT00567047 record still lists
NCT00567047 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which vildagliptin is the first listed.
NCT00567047 lists 6 locations in 5 states (Florida, Minnesota, Tennessee).
Frequently Asked Questions
What is clinical trial NCT00567047 about?
NCT00567047 is a clinical study titled "Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment". This study will evaluate the pharmacokinetics of vildagliptin and its metabolites in patients with mild, moderate or severe renal impairment and healthy volunteers.
What is the current status of trial NCT00567047?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2007-07.
What conditions does trial NCT00567047 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT00567047?
The interventions under investigation include: vildagliptin (DRUG).
Who is sponsoring clinical trial NCT00567047?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00567047 being conducted?
This trial has 6 study locations across Florida, Minnesota, Tennessee, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00567047's enrollment target sits among peer trials
96 163rd of 327 higher than 164 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
SGLT2i, Pioglitazone, and Ketone Production in T2D
RECRUITING · Phase 1
-
A Study of PATAS Trifluoroacetate Using Single Ascending Doses in Healthy Volunteers
RECRUITING · Phase 1
-
THC Effects on Glucose in Type 2 Diabetes
RECRUITING · Phase 1
-
SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
RECRUITING · Phase 1
-
Polypill for Prevention of Cardiomyopathy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia